Loss of smell (anosmia)
Also known as: Anosmia
Methodology & AI Transparency ⓘ
Loss of smell (anosmia) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code R43.0 in Preventive & Labs, Loss of smell (anosmia) (also termed Anosmia) requires fasting standardized venous in Loss of smell (anosmia) (R43.0: laboratory panels) so specialists can calibrate treatment intensity against CBC, CMP & in Loss of smell (anosmia) (R43.0: eGFR Baseline) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry R43.0: Loss of smell (anosmia) is managed within Preventive & Labs (aka Anosmia).
- 3 Typical cash cost range: Primary evaluation for Loss of smell (anosmia) incorporates fasting standardized venous in Loss of smell (anosmia) (R43.0: laboratory panels) and symptom diary review.
- 4 Top reported side effects / signs: Key Preventive & Labs biomarkers for Loss of smell (anosmia) (R43.0): CBC, CMP & in Loss of smell (anosmia) (R43.0: eGFR Baseline) & 25-Hydroxy Vitamin D, in Loss of smell (anosmia) (R43.0: Ferritin & B12) (25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R43.0)).
Ask our AI Specialists anything about Loss of smell (anosmia)
What Is Loss of smell (anosmia)?
Cataloged under federal diagnostic code R43.0 in Preventive & Labs, Loss of smell (anosmia) (also termed Anosmia) requires fasting standardized venous in Loss of smell (anosmia) (R43.0: laboratory panels) so specialists can calibrate treatment intensity against CBC, CMP & in Loss of smell (anosmia) (R43.0: eGFR Baseline) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Loss of smell (anosmia) (R43.0, Preventive & Labs) reflects early biomarker detection in Loss of smell (anosmia) (R43.0: allowing low-intensity lifestyle). longitudinal control is benchmarked via CBC, CMP & in Loss of smell (anosmia) (R43.0: eGFR Baseline).
Common Symptoms & Clinical Signs
- • Presentation of Loss of smell (anosmia) (R43.0): follow-up of borderline in Loss of smell (anosmia) (R43.0: laboratory values before)
- • Secondary Loss of smell (anosmia) clinical sign: subtle fatigue, recovery in Loss of smell (anosmia) (R43.0: lag, or micronutrient)
- • Symptom flares in Loss of smell (anosmia) correlating with CBC, CMP & in Loss of smell (anosmia) (R43.0: eGFR Baseline) deviation outside Within optimal preventive reference intervals (R43.0)
- • Functional preventive & labs impact requiring fasting standardized venous in Loss of smell (anosmia) (R43.0: laboratory panels) evaluation (R43.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Loss of smell (anosmia) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R43.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CBC, CMP & in Loss of smell (anosmia) (R43.0: eGFR Baseline) | Within optimal preventive reference intervals (R43.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Loss of smell (anosmia) (R43.0: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R43.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Loss of smell (anosmia) (R43.0: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R43.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Loss of smell (anosmia)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dapsone Gel, 5% Dapsone Gel, 5% Generic • RxCUI RXN-21922018-2310 | Sulfone | 75% | $0.5828 | $ 32.10 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Loss of smell (anosmia))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Interventions for female pattern hair: What a 2,349-Participant Study Found Further direct comparison studies of minoxidil 5% applied once a day, which could improve staying on track with medication when compared to minoxidil 2% twice daily, are still required. The Cochrane database of systematic reviews • 2012-05-16 • Meta-Analysis | N = 2,349 | 99/100 | PMID 22592723 ↗ |
| New Insights on Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and: What a 14,059-Participant Study Found Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes. Obesity (Silver Spring, Md.) • 2026-06-15 • Meta-Analysis | N = 14,059 | 99/100 | PMID 41936548 ↗ |
| New Insights on Weight loss efficiency and safety of: What a 9,873-Participant Study Found Tirzeptide can significantly reduce the weight of T2DM and patient with obesity, and it is a potential therapeutic regimen for weight-loss, but we need to be vigilant about its gastrointestinal reaction. PloS one • 2023-01-15 • Meta-Analysis | N = 9,873 | 99/100 | PMID 37141329 ↗ |
| New Insights on GLP-1 receptor agonists for weight: What a 7,024-Participant Study Found GLP-1 receptor agonists significantly increase the likelihood of weight loss versus placebo, with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated. Medicine • 2026-03-13 • Meta-Analysis | N = 7,024 | 99/100 | PMID 41824845 ↗ |
| New Insights on Safety, tolerability and sustained weight loss over 2 years with the once-daily: What a 564-Participant Study Found Liraglutide is well tolerated, sustains weight loss over 2 years and improves heart and blood vessel risk factors. International journal of obesity (2005) • 2012-06-15 • Randomized Controlled Trial | N = 564 | 93/100 | PMID 21844879 ↗ |
Loss of smell (anosmia) Patient Community & “People Like Me” Threads
Filter Loss of smell (anosmia) community threads and patient logs by age, biological sex, dosage, and treatment duration.